Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues

Valentina Bracun, Joseph Pierre Aboumsallem, Peter van der Meer, Rudolf A. de Boer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
42 Downloads (Pure)

Abstract

Purpose of the Review As the number of cancer survivors increases due to early screening and modern (antineoplastic) treatments, cancer treatment associated cardiotoxicity (CTAC) is becoming an increasing health burden that affects survival and quality of life among cancer survivors. Thus, clinicians need to identify adverse events early, in an effort to take suitable measures before the occurrence of permanent or irreversible cardiac dysfunction. Recent Findings Cardiac troponin (cTn) and B-type natriuretic peptide (BNP) have been proven to detect subclinical cardiotoxicity during antineoplastic treatment. As such, these cardio-specific biomarkers could predict which patients are at risk of developing CTAC even before the start of therapy. Nevertheless, there are inconsistent data from published studies, and the recommendations regarding the use of these biomarkers and their validity are mostly based on expert consensus opinion. In this review, we summarize available literature that evaluates biomarkers of CTAC, and we encourage strategies that integrate circulating biomarkers and cardiac imaging in identifying cancer patients that are at high risk.

Original languageEnglish
Article number67
Number of pages11
JournalCurrent oncology reports
Volume22
Issue number7
DOIs
Publication statusPublished - 9-Jun-2020

Keywords

  • Biomarkers
  • Chemotherapy
  • Cardiotoxicity
  • Heart failure
  • Cardio-oncology
  • ANTHRACYCLINE-INDUCED CARDIOTOXICITY
  • BRAIN NATRIURETIC PEPTIDE
  • BREAST-CANCER
  • TROPONIN-T
  • CARDIOVASCULAR BIOMARKERS
  • HERCEPTIN ADJUVANT
  • PLASMA-LEVELS
  • HEART
  • TRASTUZUMAB
  • THERAPY

Cite this